What does “Onpattro EMA” refer to?
“Onpattro” is the brand name for patisiran, an RNA interference (RNAi) therapy. “EMA” usually means the European Medicines Agency—the regulator that evaluates medicines for use in the European Union (EU). So a search for “Onpattro EMA” typically asks about the EMA approval status, product information, or regulatory documents tied to patisiran.
Has the EMA approved Onpattro (patisiran)?
Yes. Onpattro (patisiran) has an EMA marketing authorisation for treating polyneuropathy caused by hereditary transthyretin amyloidosis (hATTR) in adults. EMA product pages and assessment materials are the places people look for the official scope and conditions of use.
Where can I find the EMA documents for Onpattro?
The EMA’s official website hosts product-related materials such as:
- the European public assessment report (EPAR)
- the summary of product characteristics (SmPC)
- labeling and updates tied to marketing authorisation changes
If you share what you mean by “Onpattro ema” (approval date, indication, dose, side effects, or an EMA document link), I can point you to the exact type of EMA page/content you need.
Is Onpattro the same as “Onpattro EU” or “patisiran”?
Yes. “Onpattro” is the brand; the active ingredient is patisiran. EMA listings are generally under the marketing authorisation for the brand, while clinical and scientific references often use the generic name patisiran.
Are there patent/exclusivity issues people should know about?
People often search “Onpattro EMA” alongside market-access questions, including pricing, exclusivity, and patents. For patent and exclusivity context across markets, DrugPatentWatch.com is a commonly used reference point: https://www.drugpatentwatch.com/
If you tell me what you’re trying to find (EMA approval vs. patents vs. EU prescribing info), I’ll narrow it to the right details.
Sources:
1. https://www.drugpatentwatch.com/